The VICTORIA study is a randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC simulator Vericiguat in subjects with heart failure with reduced ejection fraction (HFrEF).

Resources and further information about the VICTORIA study can be found below.

Late-Breaking Clinical Trial Presentation

The VICTORIA trial was presented as a Late-Breaking Clinical Trial on March 28, 2020 at the virtual American College of Cardiology’s 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC).

Other Presentations

Press Releases & Media

Press Releases

Patient Enrollment (2016)
Study Results (March 2020)
U.S. FDA Approval (January 2021)

Media Coverage


Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, Ezekowitz JA, Butler J, O’Connor CM, Koglin J, Lam CSP, Pieske B, Roessig L, Ponikowski P, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial. Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2221.

Lam CSP, Giczewska A, Carolyn S. P. Lam, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O’Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.6455.

Ezekowitz JA, O’Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, Butler J, Lam CSP, Ponikowski P, Emdin M, Patel MJ, Pieske B, Roessig L, Hernandez AF, Armstrong PW. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. JACC Heart Fail. 2020. doi: 10.1016/j.jchf.2020.08.008.

Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors, AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM; VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382: 1883-1893. doi: 10.1056/NEJMoa1915928.

Butler J, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Comparing The Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial. Circulation. 2020; 142: 717-719. doi: 10.1161/CIRCULATIONAHA.120.047086.

Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J, Hernandez AF, Koglin J, Lam CSP, Ponikowski P, Roessig L, Voors AA, O’Connor CM, Armstrong PW; VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail. 2019;21:1596-1604. doi: 10.1002/ejhf.1664.

Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O’Connor CM. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. JACC Heart Fail. 2018;6:96-104. doi: 10.1016/j.jchf.2017.08.013.

Secondary Analyses

Data Sharing

View the VICTORIA Data Sharing Charter
Submit a Research Proposal Form



Lay Summary

VICTORIA Clinical Study Results Lay Summary (PDF)